BGE-117: HIF prolyl hydroxylase (HIF-PH) inhibitor
A core longevity pathway that drives regeneration, healing, and resilience
The Hypoxia-inducible factor (HIF) pathway is significantly associated with longevity and numerous functional outcomes in our proprietary longitudinal human cohorts.
BGE-117 is a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which protects HIF from proteasomal degradation. It has the potential to treat multiple diseases of aging through the activation of HIF target genes, which are involved in numerous biological processes including: erythropoiesis, vascular remodeling and angiogenesis, glucose uptake and glycolysis, and tissue regeneration.
BGE-117: amplifies HIF signaling, which
is linked to muscle regeneration, resilience,
and energetics
BGE-117: amplifies HIF signaling, which
is linked to muscle regeneration, resilience,
and energetics
BGE-117: amplifies
HIF signaling, which
is linked to muscle
regeneration,
resilience, and
energetics
BioAge advisor spotlight
Higher activity of hypoxia inducible factor (HIF) is associated with greater physical and cognitive function, as well as longer lifespan. Activation of HIF by blocking prolyl hydroxylase (PH) improves recovery from muscle injury. The clinically tested PH inhibitor BGE-117 could boost functional capacity by enhancing muscle repair, muscle oxidative capacity, and vascular function.
William Evans, PhD
UC Berkeley & Duke University School of Medicine
Formerly VP & Head, Muscle Metabolism Discovery Unit, GSK
